Contents
On this page
- Current status of the guideline
- Extension of the guideline beyond journal articles
- Mandatory data sharing and its unresolved legal status
- Routine disclosure of writing support and the mixed evidence on its effects
- Separation of text recycling from plagiarism
- Enforcement of reporting checklists by journals
- Implications of the data sharing trend for the manuscript
- Current developments and the scope of this article
- Implications for publication processes
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Publication · Recent trends in GPP
Changes in Good Publication Practice: Recent Developments and Emerging Trends
The current edition of GPP extended the guideline from journal articles to the full set of outputs a trial generates, and current pressure on it arises from outside publication ethics altogether: from data protection law, from similarity-detection software and from editors who enforce reporting checklists rather than requesting them. Three of these four shifts change what authors write; one changes what they are permitted to promise.
For readers who last examined GPP closely several years ago, the elements that have changed are not those most summaries emphasise. The requirement to disclose writing support has not changed in substance; it has become routine. What has changed is the range of outputs the guideline covers, the status of the data sharing statement as a reporting requirement whose legality is unsettled, and the extent to which reporting checklists are checked at the journal rather than accepted on trust. This article addresses each development and indicates where the evidence for a change is limited.
Learning objectives
- What GPP 2022 changed in scope, and which outputs it now reaches
- The dates from which the ICMJE has required a data sharing statement and a data sharing plan
- Why the data sharing requirement and European data protection law are not yet reconciled
- What the evidence shows about declared medical writing support and reporting quality, including the null result
- How text recycling is being separated out from plagiarism, and why the boundary is still contested
- Which of these trends warrant immediate action and which warrant monitoring
Common misconceptions
- “GPP is about journal articles.” This has not been the case since the 2022 edition. Plain-language summaries, enhanced digital content, congress material and results postings fall within its scope, and most internal procedures have not yet been updated accordingly.
- “A data sharing statement means the data will be shared.” It means that a statement is required. Whether sharing is lawful depends on the consent actually obtained and on the applicable data protection regime, and the research literature does not agree that these are reconciled.
- “Declaring a medical writer improves reporting quality.” The two largest studies disagree. Mills and colleagues, in F1000Research, found mean adherence to CONSORT for Abstracts of 64.3% with writing support against 66.5% without, a difference that was not statistically significant (p=0.30).
- “Reusing your own methods text is now accepted.” It is being treated as a distinct category rather than as plagiarism, which is not equivalent to acceptance. Moskovitz argues that much of it is harmless and unavoidable; the detection literature flags it regardless of authorship; and the journal’s own policy remains decisive.
- “Reporting guidelines are an author-side formality.” Hopewell and colleagues showed in BMJ that when editors actively implemented CONSORT for abstracts, abstract reporting changed, indicating that the point of enforcement has moved to the journal.
Current status of the guideline
The current edition is GPP 2022, published by DeTora and colleagues in Annals of Internal Medicine, volume 175, issue 9, pages 1298 to 1304, online on 30 August 2022 6. Its development merits brief description because it bears on the weight the document carries: 38 invited experts gave feedback before submission, and an open reviewer call returned more than 120 sets of comments, representing the input of hundreds of professionals 5. ISMPP, which coordinated it, had more than 2,200 members at the time of publication 5.
This constitutes a broad base for a voluntary guideline, and it is the reason GPP 2022 is treated as the standard of practice by sponsors and by many journals, despite having no regulatory force 5,6. For the four-edition history behind it, see the evolution of GPP; for the requirements themselves set out item by item, see the reporting standards reference.
Extension of the guideline beyond journal articles
Every GPP edition before 2022 assumed the governed output was a paper or a congress presentation 15,19. That assumption no longer held. The results of a single trial now reach their audiences through a plain-language summary, a graphical abstract, a video abstract, a slide set for field medical teams, a registry results posting and sometimes material written for patients rather than clinicians — none of which were clearly inside the older editions’ remit, and several of which did not exist when GPP2 was written.
GPP 2022 extended the principles across that range 6. The practical consequence is prosaic but burdensome: the disclosure, authorship and accuracy requirements that a publications team already applies to the manuscript must now be applied to a dozen derivative outputs produced by different people on different timelines, often after the paper has been published. In most organisations the plain-language summary and the enhanced content are drafted by whoever has capacity, from the published paper, with no contributorship record and no declaration of who funded the drafting.
In Pubrica’s experience, this is the single most common gap. It is also the easiest to close, because the required text already exists in the manuscript.
Mandatory data sharing and its unresolved legal status
The sequence is clear, and the dates are significant. Since 1 July 2018 the ICMJE has required that manuscripts reporting clinical trial results contain a data sharing statement, and trials that began enrolment on or after 1 January 2019 must include a data sharing plan in their registration 1. This is not a GPP innovation; GPP follows it, as GPP has generally followed the journals.
What remains unsettled is whether such sharing is lawful. The European General Data Protection Regulation applies to health data used in research, and the research literature on how it interacts with data sharing obligations is unresolved rather than merely complicated 12,14. Chassang, in ecancermedicalscience, set out the Regulation’s effect on scientific research; Vlahou and colleagues argued in Hypertension that research ethics and data protection law still need harmonising; and Christofidou and colleagues, in Frontiers in Medicine, examined the consent models actually in use and asked whether the Regulation’s data altruism mechanism offers the research community a workable route to reusing health data 4,7,12.
For an author, this reduces to a single discipline. The data sharing statement must describe a mechanism that is lawful under the consent participants actually gave, and if it is not, the statement should state that the data cannot be shared and why. A statement promising sharing that the consent form does not support is worse than a statement declining to share: it is an undertaking that cannot be honoured, in the permanent record. “Available on request” with no route, no timeframe and no conditions is inadequate and is increasingly queried at submission.
Routine disclosure of writing support and the mixed evidence on its effects
Declaring professional writing support, by name and funder, is now routine rather than contentious. The position was argued for by the professional bodies two decades ago — Hamilton and Royer for AMWA, Jacobs and Wager for EMWA in Current Medical Research and Opinion, Norris and colleagues for ISMPP — against the background Gotzsche and colleagues described in PLoS Medicine, and against the documented practice Ross and colleagues and Hill and colleagues set out in the rofecoxib and ADVANTAGE analyses 27,29,30. That argument is settled.
What is not settled is whether declared writing support is associated with better reporting. Gattrell and colleagues, in BMJ Open, examined randomised controlled trial reports and found an association with more complete reporting against CONSORT. Mills and colleagues, in F1000Research, examined 463 randomised controlled trial articles from five high-impact journals and found mean adherence to CONSORT for Abstracts of 64.3% with writing support against 66.5% without, with a p value of 0.30, indicating no significant difference 11,13. In the same study, writing support was associated with better reporting of harms (relative risk 2.04, 95% confidence interval 1.37 to 3.03) and of funding source (RR 1.75, 95% CI 1.18 to 2.60), but worse reporting of the study setting (RR 0.40, 95% CI 0.23 to 0.70) 11.
A cautious reading is that writing support is associated with better reporting of the items a professional is specifically briefed to include, and with no better, and sometimes worse, reporting of items that are not treated as a disclosure obligation. This is a finding about briefs and checklists rather than about writers. Where a sponsor commissions medical writing support, the item list provided to the writer appears to contribute more than the engagement itself.
Findings from 463 randomised controlled trial articles in five high-impact general medical journals; 95% confidence intervals were 1.37 to 3.03 for harms, 1.18 to 2.60 for funding source and 0.23 to 0.70 for study setting. Source: Mills I, Sheard C, Hays M, Douglas K, Winchester CC, Gattrell WT. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals. F1000Research.
Separation of text recycling from plagiarism
Self-reuse was formerly handled as a lesser form of plagiarism. It is now increasingly treated as its own category with its own rules, and the shift is incomplete. COPE’s Core Practices require a journal to have a policy on it, which has had the effect of making the policies visible and showing how widely they differ 3. Moskovitz, in Science and Engineering Ethics, argued that reusing one’s own description of an unchanged procedure is frequently both harmless and the clearest way to write it, and Anson and Moskovitz’s text-analytic study in Accountability in Research found recycling to be common in recently published STEM research articles rather than exceptional 8,10.
Two consequences follow. First, detection practice has not relaxed: Foltynek, Meuschke and Gipp’s systematic review in ACM Computing Surveys describes a detection literature that identifies overlap regardless of whose text it is, so recycled methods will be flagged whatever the ethics 9. Second, the practical rule is unchanged even though ethical opinion has shifted: authors should disclose the reuse in the cover letter, cite the earlier paper and check the journal’s own policy, because it governs where the sources disagree. For the surrounding distinctions, see duplicate publication and the consequences of plagiarism; a similarity report obtained before an editor runs one requires a plagiarism check.
Enforcement of reporting checklists by journals
The less conspicuous change with the most immediate effect on drafting is that reporting guidelines have moved from author aspiration to editorial process. Hopewell and colleagues ran an interrupted time series analysis in BMJ of what happened when editors at high-impact medical journals actively implemented the CONSORT guidance for abstracts, and reporting of abstracts changed 17. Hopewell and colleagues’ earlier CONSORT for Abstracts explanation in PLoS Medicine supplied what editors were implementing 22. Turner and colleagues’ Cochrane review in Systematic Reviews assessed the broader question of whether CONSORT improves reporting completeness, and the answer there is more guarded 16.
For a writer, this is a matter of sequencing rather than principle. If the checklist is applied at the journal, it must be applied during drafting, not assembled at submission, by which point the missing items are missing data rather than missing sentences. Which checklist applies is determined by design: CONSORT 2010 from Schulz, Altman and Moher for parallel-group randomised trials, PRISMA from Moher and colleagues for systematic reviews, STROBE from von Elm and colleagues for observational studies 18,20,28. Our reporting guidelines page maps design to checklist.
Implications of the data sharing trend for the manuscript
Of the five trends above, the one that most often produces a weak sentence in an otherwise careful manuscript is the data sharing statement. The pair below are for the same trial, where the consent obtained supports controlled sharing of de-identified data with named conditions and nothing more.
A data sharing statement for the same trial, written twice
Will be queried
Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request.
No definition of what would be shared. Individual participant data, summary tables and the analysis plan are different undertakings.
“Reasonable” is undefined and unreviewable. The corresponding author decides, with no stated criteria, possibly years after leaving the institution.
No timeframe, no route, no conditions. There is nothing here a reader could act on and nothing an editor can check.
Silent on consent. The statement implies that sharing is possible without stating whether participants agreed to it, which is the question that determines whether it is lawful.
Describes a mechanism
Data availability: De-identified individual participant data underlying the results reported in this article, together with the statistical analysis plan and the redacted protocol, will be available from 12 months after publication for 5 years. Access is limited to researchers whose proposed use has been approved by an independent review panel and who have signed a data access agreement; requests are made through the sponsor’s data request portal. The informed consent obtained from participants permits sharing of de-identified data for secondary research of this kind, and does not permit transfer of identifiable data or re-identification; requests requiring either will be declined. The full consent text is available in the supplementary material.
Names the datasets and documents, so the undertaking is specific.
Names the gatekeeper, the review step and the agreement, so access does not rest on one person’s judgement of “reasonable”.
Gives a start date, a duration and a route, which makes the commitment verifiable.
States what the consent does and does not permit, and declines in advance the requests it cannot support — the thing the data protection literature says must be addressed.
The first version is the most common data availability statement in the literature, and it satisfies the ICMJE requirement only in form. The second does not promise more; in one respect it promises less, by ruling out requests the consent cannot support. This is intentional: a statement is an undertaking in the permanent record, and the only safe statement is one that can be honoured.
Current developments and the scope of this article
Two developments are visibly in progress, and no verified source in this article’s evidence base settles either; they are therefore identified here rather than covered. The first is generative artificial intelligence in drafting and its disclosure: journals and professional bodies have been issuing positions on it, but none of these is in the reference pool for this page, and guidance that cannot be cited is not characterised here. The second is preprinting of company-sponsored trial results, which raises prior-publication and disclosure questions the current edition addresses only in general terms.
A third, slower change merits mention because it affects what authors can promise rather than what they write. The data protection position described above is the subject of active legal and policy work, and Christofidou and colleagues’ examination of consent models and data altruism indicates where the research community is seeking a way forward 4. Nothing in that literature currently permits an author to promise more sharing than the consent form supports.
The remainder of this page should be treated as current and the matters above as open. Where a sponsor’s procedure offers a confident answer on AI disclosure or preprints, its sources should be established.
Implications for publication processes
Four of these trends can be acted on within a quarter, and the fourth is the one most teams omit. The publication procedure’s output list should be extended to name plain-language summaries, enhanced content and results postings, with the same disclosure and contributorship requirements attached to each. The standing data sharing statement should be rewritten to describe a mechanism rather than a willingness, and checked against the consent form rather than against the last manuscript. Writers should be given an explicit item list drawn from the applicable reporting guideline, because the Mills findings suggest that this is where the benefit lies. Finally, the checklist should be applied while the paper is being drafted, not at submission.
Where any of this touches a protocol that has not yet been registered, the registration itself now carries obligations: see clinical trials protocol registration. Where it touches the broader ethics framework, see the publication ethics hub.
Five current trends, and what each one asks you to change
| Trend | What changed | What to do about it | Where it comes from |
|---|---|---|---|
| Scope beyond the journal | GPP 2022 reaches plain-language summaries, enhanced content, congress material and results postings | Add every derivative output to the procedure’s list and attach disclosure and contributorship requirements to each | DeTora et al., Annals of Internal Medicine (2022) |
| Data sharing as a reporting item | A data sharing statement has been required in trial-results manuscripts since 1 July 2018; a data sharing plan in registration for trials enrolling from 1 January 2019 | Write a statement that names what, to whom, from when, by what route and on what condition, or that states that sharing is not possible and why | ICMJE Recommendations |
| Data protection as a constraint | The legality of sharing is unresolved rather than settled, and depends on the consent actually obtained | Check the statement against the consent form, not against the journal’s wording; promise nothing the consent does not support | Chassang, ecancermedicalscience; Vlahou et al., Hypertension; Christofidou et al., Frontiers in Medicine |
| Writing support as ordinary disclosure | Named disclosure is now routine; the evidence that it improves reporting is mixed and partly null | Brief writers with an explicit reporting-checklist item list; do not rely on the engagement alone | Mills et al., F1000Research; Gattrell et al., BMJ Open |
| Checklists enforced editorially | Editorial implementation of CONSORT for abstracts changed abstract reporting | Apply the checklist during drafting; at submission the gaps are missing data, not missing sentences | Hopewell et al., BMJ; Turner et al., Systematic Reviews |
Compiled from the sources named in each row, as cited in the reference list below. The trends represent Pubrica’s characterisation of the direction of travel, not a formal statement from any issuing body.
Key points
Key points
GPP 2022 extended the guideline beyond the journal article to the full set of outputs a study generates, and most internal procedures have not followed. Data sharing statements have been required in trial-results manuscripts since 1 July 2018, and data sharing plans in registration for trials enrolling from 1 January 2019; however, whether sharing is lawful depends on the consent obtained and the data protection regime, and the research literature does not treat that question as settled. Disclosure of writing support is now routine, but its effect on reporting quality is not established: Mills and colleagues found CONSORT for Abstracts adherence of 64.3% against 66.5%, with no significant difference. Text recycling is becoming a distinct category, and reporting checklists are increasingly enforced at the journal rather than requested, which means that they belong in drafting rather than at submission.
Application to your study
Application to your study
- Every output the study will generate should be listed (paper, abstract, poster, plain-language summary, graphical or video abstract, slide set, results posting and patient-facing material), and each should be confirmed as having named contributors and a funding declaration.
- The standard data availability statement should be rewritten as a description of a mechanism. It should specify what data are available, to whom, from when, for how long, by what route, under what agreement and on what consent basis.
- The consent form should be read before the data sharing statement is written, not afterwards. Where consent does not support reuse, this should be stated in the statement together with the reason.
- Writers should be given an explicit item list from the applicable reporting guideline. The Mills findings indicate that briefed items improved and unbriefed items did not, suggesting that the brief is where the gain lies.
- Harms and study setting should be added to that list by name. These are the two items that the evidence singles out, in opposite directions.
- The checklist should be applied during drafting. If editors now check it, a gap identified at submission is usually a data gap rather than a wording gap.
- Any recycled text from the authors’ own earlier papers should be disclosed in the cover letter, the source paper should be cited, and the target journal’s policy, which governs where the guidance disagrees, should be checked.
- The sources cited by any confident internal position on artificial intelligence (AI) disclosure or preprints should be verified. Both areas are evolving, and a procedure that appears settled on either may be ahead of its evidence.
Frequently asked questions
GPP 2022, by DeTora and colleagues, published in Annals of Internal Medicine volume 175, issue 9, pages 1298 to 1304, and released online on 30 August 2022. It was developed with feedback from 38 invited experts before submission, followed by an open reviewer call that returned more than 120 sets of comments representing the input of hundreds of professionals; ISMPP, which coordinated the work, had more than 2,200 members at the time. It supersedes GPP3 from 2015 and is the current edition. Procedures still citing GPP3 or GPP2 should be rechecked, because the scope of the guideline changed at the most recent revision.
Scope. Every earlier edition assumed the output being governed was a journal article or a congress presentation. GPP 2022 extends the principles to the full range of outputs a study now generates: plain-language summaries, enhanced and digital content such as graphical and video abstracts, slide sets, registry results postings and material written for patients rather than clinicians. In practice this is the most commonly unmet requirement, because those derivative outputs are usually produced after the paper, by different people, with no contributorship record and no statement of who funded the drafting — even in organisations whose manuscript process is careful.
The ICMJE has required that manuscripts reporting clinical trial results contain a data sharing statement since 1 July 2018, and has required a data sharing plan in the trial registration for trials that began enrolment on or after 1 January 2019. The requirement mandates the statement, not the sharing. A statement that explains transparently why data cannot be shared (for instance, because the consent obtained does not support it) satisfies the requirement. A statement reading “available from the corresponding author upon reasonable request”, with no named data, no timeframe, no route and no conditions, satisfies it only in form and is increasingly queried.
Not categorically, but it is a genuine constraint and the literature does not treat the position as resolved. Chassang, in ecancermedicalscience, set out the Regulation’s effect on scientific research. Vlahou and colleagues argued in Hypertension that research ethics and data protection law have yet to be harmonised. Christofidou and colleagues, in Frontiers in Medicine, examined the consent models in use and whether the Regulation’s data altruism mechanism offers a route for reusing health data. The practical requirement for an author is narrower than the legal debate: the statement should describe only a mechanism that the consent participants actually gave will support, and should state explicitly what it will not support.
The two main studies disagree, so the answer is that it does so partly, and for specific items. Gattrell and colleagues, in BMJ Open, found declared writing support associated with more complete CONSORT reporting in randomised trial reports. Mills and colleagues, in F1000Research, examined 463 randomised controlled trial articles from five high-impact journals and found mean adherence to CONSORT for Abstracts of 64.3% with writing support against 66.5% without, with p=0.30, indicating no significant difference overall. Within the same study, support was associated with better reporting of harms (RR 2.04) and funding source (RR 1.75) but worse reporting of the study setting (RR 0.40). The pattern suggests that briefed items improve and unbriefed items do not.
It has become a distinct category, which is not the same thing. COPE’s Core Practices require journals to hold a policy on it, which has made the range of positions visible rather than narrowing it. Moskovitz, in Science and Engineering Ethics, argues that reusing one’s own description of an unchanged procedure is often harmless and frequently the clearest way to write it, and Anson and Moskovitz found in Accountability in Research that recycling is common in published STEM articles. Detection, however, has not relaxed: Foltynek, Meuschke and Gipp’s review in ACM Computing Surveys describes methods that flag overlap irrespective of authorship, and journals set their own policies. Authors should disclose the reuse, cite the earlier paper and check the journal’s rules.
This page does not answer that question, because no source in this article’s verified evidence base addresses it, and characterising guidance that cannot be cited would be worse than leaving a gap. Positions have been issued by journals and professional bodies, and they are changing. The practical course is to check the target journal’s instructions for authors and the sponsor’s own policy, both of which are more current than any teaching page, and to examine any confident internal answer with the question applied to any manuscript claim: what is its source?
The enforcement point has moved from the author to the journal. Hopewell and colleagues ran an interrupted time series analysis in BMJ of what happened when editors at high-impact medical journals actively implemented the CONSORT guidance for abstracts, and abstract reporting changed. Turner and colleagues’ Cochrane review in Systematic Reviews takes a more guarded view of CONSORT’s overall effect on reporting completeness, so the evidence of benefit is not settled. From a drafting standpoint, however, the implication is the same: the checklist should be applied during writing, because by submission an unmet item is usually a missing measurement rather than a missing sentence.
References
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
- International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
- Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
- Christofidou M, Arvanitis TN, Kalra D, Lea N, Shabani M, Coorevits P. Data altruism and the 'consent' question: a study into the 'consent' models used under the GDPR and how the data altruism mechanism can act as a potential solution for the research community in the reuse of health data. Frontiers in Medicine. 2025;11:1489925. doi:10.3389/fmed.2024.1489925 read 9 October 2026. doi.org/10.3389/fmed.2024.1489925
- International Society for Medical Publication Professionals. GPP 2022: Good Publication Practice guidelines for company-sponsored biomedical research published in Annals of Internal Medicine (press release). ISMPP. 2022. read 9 October 2026. ismpp.org
- DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
- Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, et al. Data sharing under the General Data Protection Regulation: time to harmonize law and research ethics? Hypertension. 2021;77:1029-1035. doi:10.1161/HYPERTENSIONAHA.120.16340 read 9 October 2026. doi.org/10.1161/HYPERTENSIONAHA.120.16340
- Anson IG, Moskovitz C. Text recycling in STEM: a text-analytic study of recently published research articles. Accountability in Research. 2020. doi:10.1080/08989621.2020.1850284 read 9 October 2026. doi.org/10.1080/08989621.2020.1850284
- Foltynek T, Meuschke N, Gipp B. Academic plagiarism detection: a systematic literature review. ACM Computing Surveys. 2019;52(6):1-42. doi:10.1145/3345317 read 9 October 2026. doi.org/10.1145/3345317
- Moskovitz C. Text recycling in scientific writing. Science and Engineering Ethics. 2019;25(3):813-851. doi:10.1007/s11948-017-0008-y read 9 October 2026. doi.org/10.1007/s11948-017-0008-y
- Mills I, Sheard C, Hays M, Douglas K, Winchester CC, Gattrell WT. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals. F1000Research. 2017;6:1489. doi:10.12688/f1000research.12268.2 read 9 October 2026. doi.org/10.12688/f1000research.12268.2
- Chassang G. The impact of the EU general data protection regulation on scientific research. ecancermedicalscience. 2017;11:709. doi:10.3332/ecancer.2017.709 read 9 October 2026. doi.org/10.3332/ecancer.2017.709
- Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open. 2016;6(2):e010329. doi:10.1136/bmjopen-2015-010329 read 9 October 2026. doi.org/10.1136/bmjopen-2015-010329
- European Union. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (General Data Protection Regulation). Official Journal of the European Union. 2016. read 9 October 2026. frontiersin.org
- Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
- Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Systematic Reviews. 2012;1:60. read 9 October 2026. care-statement.org
- Hopewell S, Ravaud P, Baron G, Boutron I. Effect of editors' implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. BMJ. 2012;344:e4178. read 9 October 2026. care-statement.org
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine. 2010;152:726-732. read 9 October 2026. care-statement.org
- Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx M-E, Patel M, Sanes-Miller C, Yarker YE. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. doi:10.1136/bmj.b4330 read 9 October 2026. doi.org/10.1136/bmj.b4330
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6:e1000097. read 9 October 2026. care-statement.org
- Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Medicine. 2009;6(2):e1000023. read 9 October 2026. archive.emwa.org
- Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF; CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Medicine. 2008;5:e20. read 9 October 2026. care-statement.org
- Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299:1800-1812. read 9 October 2026. archive.emwa.org
- Angell M. Industry-sponsored clinical research: a broken system. JAMA. 2008;300:1069-1071. read 9 October 2026. archive.emwa.org
- Titus SL, Wells JA, Rhoades LJ. Repairing research integrity. Nature. 2008;453:980-982. read 9 October 2026. archive.emwa.org
- Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals of Internal Medicine. 2008;149:251-258. read 9 October 2026. archive.emwa.org
- Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, et al. International Society for Medical Publication Professionals (ISMPP) position statement. Current Medical Research and Opinion. 2007;23:1837-1840. read 9 October 2026. archive.emwa.org
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808. read 9 October 2026. care-statement.org
- Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. Current Medical Research and Opinion. 2005;21:317-321. read 9 October 2026. archive.emwa.org
- Hamilton CW, Royer MG; AMWA 2002 Task Force on the Contributions of Medical Writers to Scientific Publications. AMWA position statement on the contributions of medical writers to scientific publications. AMWA Journal. 2003;18:13-16. read 9 October 2026. archive.emwa.org
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Current Medical Research and Opinion. 2003;19(3):149-154. doi:10.1185/030079903125001767 read 9 October 2026. doi.org/10.1185/030079903125001767
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Current Medical Research and Opinion. 2003;19(3):147-148. read 9 October 2026. ismpp.org
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Changes in Good Publication Practice: Recent Developments and Emerging Trends. Pubrica. https://pubrica.com/academy/concepts-definitions/recent-trends-of-gpp/
Pubrica Academy. “Changes in Good Publication Practice: Recent Developments and Emerging Trends.” Pubrica, 9 Oct. 2026, pubrica.com/academy/concepts-definitions/recent-trends-of-gpp/.
Pubrica Academy (2026) Changes in Good Publication Practice: Recent Developments and Emerging Trends. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/recent-trends-of-gpp/ (Accessed: 15 October 2026).
Pubrica Academy. “Changes in Good Publication Practice: Recent Developments and Emerging Trends.” Pubrica. October 9, 2026. https://pubrica.com/academy/concepts-definitions/recent-trends-of-gpp/
Pubrica Academy, ‘Changes in Good Publication Practice: Recent Developments and Emerging Trends’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/concepts-definitions/recent-trends-of-gpp/> accessed 15 October 2026.
Pubrica Academy. Changes in Good Publication Practice: Recent Developments and Emerging Trends. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/recent-trends-of-gpp/
Pubrica Academy, “Changes in Good Publication Practice: Recent Developments and Emerging Trends,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/recent-trends-of-gpp/
@misc{recent_trends_of_gpp_2026,
author = {{Pubrica Academy}},
title = {Changes in Good Publication Practice: Recent Developments and Emerging Trends},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/recent-trends-of-gpp/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Trend-gap review for a current publication programme
This review should be conducted once per programme, not per manuscript. It tests whether the publication process has absorbed the changes described above. Each unchecked box represents a specific piece of text or a specific owner that does not currently exist.
GPP TREND-GAP REVIEW
Programme / study: ______________________ Reviewed by: ____________
Date: ____________ Edition cited in local procedure: ____________
1. OUTPUT INVENTORY (GPP 2022 scope)
For each output, record the named contributors and the funder of drafting:
Primary manuscript ............ contributors ____ funder ____
Congress abstract / poster .... contributors ____ funder ____
Plain-language summary ........ contributors ____ funder ____
Graphical / video abstract .... contributors ____ funder ____
Slide set or field material ... contributors ____ funder ____
Registry results posting ...... contributors ____ funder ____
Patient-facing material ....... contributors ____ funder ____
[ ] Every row above has both fields completed, or is marked not applicable
2. DATA SHARING STATEMENT
[ ] States WHAT data and documents
[ ] States TO WHOM, and who decides
[ ] States FROM WHEN and FOR HOW LONG
[ ] States BY WHAT ROUTE
[ ] States the AGREEMENT or conditions required
[ ] States what the consent does NOT permit
[ ] Has been read against the consent form by a named person: ____________
[ ] Registration includes a data sharing plan (trials enrolling from 2019)
3. WRITING SUPPORT BRIEF
Reporting guideline applicable to this design: ______________________
[ ] The writer has been given the checklist, item by item
[ ] Harms reporting is named explicitly in the brief
[ ] Study setting is named explicitly in the brief
[ ] Funding source reporting is named explicitly in the brief
[ ] Writing support disclosure text is drafted: person, employer, funder,
scope, consent to be named
4. CHECKLIST TIMING
[ ] The checklist is being completed DURING drafting
[ ] Any item that cannot be reported has been identified as a DATA gap and
escalated, not left as a wording problem
Items that cannot be reported: ______________________________________
5. TEXT REUSE
[ ] Recycled text from our own earlier publications is identified
[ ] The earlier paper is cited
[ ] The reuse is disclosed in the cover letter
[ ] The target journal's recycling policy has been read
6. OPEN ITEMS WITH NO SETTLED GUIDANCE
AI use in drafting -- target journal policy checked? ____ Sponsor policy? ____
Preprint planned? ____ Prior-publication position confirmed with editor? ____
Notes: ______________________________________________________ Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s publication-support team addresses the two areas in which these trends have the greatest practical effect: derivative outputs for which no procedure exists, and data sharing statements that have not been checked against the consent form. Pubrica drafts the disclosure, contributorship and data availability text for the full output set rather than the manuscript alone, and briefs writers on the applicable reporting checklist item by item, because that is where the published evidence suggests the benefit lies. Where guidance is genuinely unsettled, Pubrica states this and assists in obtaining the target journal’s position in writing.